A randomized phase 2 study of nivolumab plus ipilimumab or nivolumab plus cabozantinib as first-line therapy, with protocol-specified lenvatinib plus everolimus in the second-line, in metastatic TFE-rearranged renal cell carcinoma (ESMO Asia 2026) - Oct 1, 2026 - Abstract #410RO; Pres time: Dec 4, 2026; 03:02 PM - 03:07 PM; Location: Hall 402; No abstract available
Clinical • Metastases • P2 data • Genito-urinary Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|